Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Michael E. Trautmann"'
Autor:
John Stewart, Richard E Pratley, Marcus Hompesch, OakPil Han, Michael E Trautmann, Christopher H Sorli, SeungJae Baek, Stephan Jacob, Alka Shaunik, Kun-Ho Yoon
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/5931bc3417f34cafa1641fb7edb77921
Autor:
John Stewart, Marcus Hompesch, Jahoon Kang, OakPil Han, Michael E Trautmann, Christopher H Sorli, Ike Ogbaa, Linda Morrow
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
Introduction To evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabe
Externí odkaz:
https://doaj.org/article/0f97f81f7a354a72815a206a028b3d29
Autor:
Michael Derwahl, Kun-Ho Yoon, Michael E. Trautmann, Stefano Del Prato, Jahoon Kang, Christopher H. Sorli, John Stewart, Alfonso Soto
Publikováno v:
Diabetes, Obesity & Metabolism
Aims To determine the optimal dose(s) of once‐monthly administration of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), in patients with type 2 diabetes (T2D) inadequately controlled on metformin. Materials
Autor:
Se Chang Kwon, Michael E. Trautmann, Christopher H. Sorli, Marcus Hompesch, John Stewart, Kun-Ho Yoon, Jahoon Kang
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To assess the efficacy, safety and pharmacokinetic/pharmacodynamic properties of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist, in patients with type 2 diabetes (T2D). Research design and methods Two randomized, doub
Autor:
Jahoon Kang, Oakpil Han, John Stewart, Michael E. Trautmann, Ike Ogbaa, Marcus Hompesch, Linda Morrow, Christopher H. Sorli
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)
BMJ Open Diabetes Research & Care
BMJ Open Diabetes Research & Care
IntroductionTo evaluate the effects of efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA), on gastric emptying, glucose metabolism, and islet beta-cell function versus liraglutide and placebo in people with type 2 diabet
Autor:
Richard E. Pratley, Stephan Jacob, Jahoon Kang, John Stewart, Kun-Ho Yoon, Michael E. Trautmann, Christopher H. Sorli, Marcus Hompesch, Oakpil Han
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To evaluate the safety of efpeglenatide, a long‐acting glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), and its effects on body weight management in adults without diabetes. Materials and methods In this phase II, randomized, placebo
Publikováno v:
Diabetologie und Stoffwechsel. 12:S1-S84
Autor:
George E. Dailey, Christopher H. Sorli, In Young Choi, Ulrich Wendisch, Jahoon Kang, Marcus Hompesch, John A. Stewart, Cristobal Morales, Michael E. Trautmann, Ike Ogbaa, Kun-Ho Yoon, Julio Rosenstock
Publikováno v:
Diabetes. 68
Once-weekly (QW), subcutaneous efpeglenatide (EFPEG) is a long-acting GLP-1 RA for T2D management. In EXCEED 203 (NCT02057172), EFPEG QW significantly reduced HbA1c vs. placebo (PBO) for early T2D (naïve/metformin monotherapy). This post hoc subanal
Autor:
John A. Stewart, Stephan Jacob, Ike Ogbaa, Michael E. Trautmann, Richard E. Pratley, Kun-Ho Yoon, Christopher H. Sorli, Jahoon Kang, Oakpil Han, Marcus Hompesch
Publikováno v:
Diabetes. 68
Once-weekly (QW) subcutaneous efpeglenatide (efpeg) is a long-acting GLP-1 RA being developed to improve glycemic control in patients with T2D. In the BALANCE 205 study (NCT02075281) in patients with obesity (median BMI 34.9 [28.1−57.7] kg/m2) with